Market
Three manufacturing plants also to transfer, along with 565 employees Deal expected to close by third quarter of 2027

Sanofi will transfer 20 established medicines and three manufacturing plants to German pharmaceutical company Cheplapharm and secure a 26.4% stake in the company.
According to Fierce Pharma on the 16th, local time, Sanofi will acquire a 26.4% stake in Cheplapharm as part of the deal, divesting assets related to mature medicines.
Unlike a conventional pharmaceutical company, Cheplapharm specializes in maintaining and managing mature medicines. It acquires branded medicines whose patents have expired, helping pharmaceutical companies focus on developing innovative new drugs.
The two companies have worked together for more than 10 years. Cheplapharm has outsourced production until now, but under the deal it will take over Sanofi's Lovenox manufacturing facilities in Hungary, Singapore and France and shift to in-house production. A total of 565 employees at the plants will transfer.
Sanofi signed the deal as CEO Belén Garijo, who took office in May, moved to strengthen the company's innovation capabilities to support medium- and long-term growth. Sanofi suffered several setbacks in research and development (R&D) in 2025, leading to changes in its leadership.
Thomas Grenier, Sanofi's executive vice president and head of General Medicines, said, "This partnership and our stake in Cheplapharm demonstrate our commitment to ensuring patients continue to benefit from today's essential medicines while pursuing tomorrow's innovations."
Sanofi said the deal will not affect its 2026 financial outlook. The transfer of the medicine portfolio will begin in the first quarter of 2027, followed by the transfer of the manufacturing facilities. The deal is expected to close by the third quarter of 2027.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss